187 related articles for article (PubMed ID: 19521244)
1. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.
Young SP; Zhang H; Corzo D; Thurberg BL; Bali D; Kishnani PS; Millington DS
Genet Med; 2009 Jul; 11(7):536-41. PubMed ID: 19521244
[TBL] [Abstract][Full Text] [Related]
2. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
An Y; Young SP; Kishnani PS; Millington DS; Amalfitano A; Corz D; Chen YT
Mol Genet Metab; 2005 Aug; 85(4):247-54. PubMed ID: 15886040
[TBL] [Abstract][Full Text] [Related]
3. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
[TBL] [Abstract][Full Text] [Related]
4. Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening.
Chien YH; Goldstein JL; Hwu WL; Smith PB; Lee NC; Chiang SC; Tolun AA; Zhang H; Vaisnins AE; Millington DS; Kishnani PS; Young SP
JIMD Rep; 2015; 19():67-73. PubMed ID: 25681082
[TBL] [Abstract][Full Text] [Related]
5. The decision-making levels of urine tetrasaccharide for the diagnosis of Pompe disease in the Turkish population.
Canbay E; Vural M; Kalkan Uçar S; Sezer ED; Karasoy H; Yüceyar AN; Çoker M; Sözmen EY
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):391-395. PubMed ID: 32069240
[TBL] [Abstract][Full Text] [Related]
6. [Tetra-saccharide glucose as a diagnostic biomarker for Pompe disease: a study with 35 patients].
Bobillo Lobato J; Durán Parejo P; Tejero Díez P; Jiménez Jiménez LM
Med Clin (Barc); 2013 Aug; 141(3):106-10. PubMed ID: 23756115
[TBL] [Abstract][Full Text] [Related]
7. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
[TBL] [Abstract][Full Text] [Related]
8. Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease.
de Moraes MBM; de Souza HMR; de Oliveira MLC; Peake RWA; Scalco FB; Garrett R
Metabolomics; 2023 Mar; 19(4):29. PubMed ID: 36988742
[TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
[TBL] [Abstract][Full Text] [Related]
10. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry.
Young SP; Stevens RD; An Y; Chen YT; Millington DS
Anal Biochem; 2003 May; 316(2):175-80. PubMed ID: 12711338
[TBL] [Abstract][Full Text] [Related]
11. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
Khan AA; Case LE; Herbert M; DeArmey S; Jones H; Crisp K; Zimmerman K; ElMallah MK; Young SP; Kishnani PS
Genet Med; 2020 May; 22(5):898-907. PubMed ID: 31904026
[TBL] [Abstract][Full Text] [Related]
12. Diurnal variability of glucose tetrasaccharide (Glc
Young SP; Khan A; Stefanescu E; Seifts AM; Hijazi G; Austin S; Kishnani PS
JIMD Rep; 2021 Mar; 58(1):37-43. PubMed ID: 33728245
[TBL] [Abstract][Full Text] [Related]
13. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
[TBL] [Abstract][Full Text] [Related]
14. Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort.
Piraud M; Pettazzoni M; de Antonio M; Vianey-Saban C; Froissart R; Chabrol B; Young S; Laforêt P;
Mol Genet Metab Rep; 2020 Jun; 23():100583. PubMed ID: 32382504
[No Abstract] [Full Text] [Related]
15. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
[TBL] [Abstract][Full Text] [Related]
16. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.
Elder ME; Nayak S; Collins SW; Lawson LA; Kelley JS; Herzog RW; Modica RF; Lew J; Lawrence RM; Byrne BJ
J Pediatr; 2013 Sep; 163(3):847-54.e1. PubMed ID: 23601496
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen.
Kumlien J; Chester MA; Lindberg BS; Pizzo P; Zopf D; Lundblad A
Clin Chim Acta; 1988 Aug; 176(1):39-48. PubMed ID: 3168292
[TBL] [Abstract][Full Text] [Related]
18. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.
Thurberg BL; Lynch Maloney C; Vaccaro C; Afonso K; Tsai AC; Bossen E; Kishnani PS; O'Callaghan M
Lab Invest; 2006 Dec; 86(12):1208-20. PubMed ID: 17075580
[TBL] [Abstract][Full Text] [Related]
19. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.
Van den Hout JM; Reuser AJ; de Klerk JB; Arts WF; Smeitink JA; Van der Ploeg AT
J Inherit Metab Dis; 2001 Apr; 24(2):266-74. PubMed ID: 11405345
[TBL] [Abstract][Full Text] [Related]
20. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
Levine JC; Kishnani PS; Chen YT; Herlong JR; Li JS
Pediatr Cardiol; 2008 Nov; 29(6):1033-42. PubMed ID: 18661169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
